Background
==========

Kabuki syndrome (KS, MIM \#147920), also known as Niikawa-Kuroki syndrome, is a rare, multiple congenital anomalies/mental retardation syndrome characterized by a peculiar face, which is defined by long palpebral fissures with eversion of the lateral third of the lower eyelids, short columella with a broad and depressed nasal tip, prominent ears, and a cleft or high-arched palate. Additional features include short stature, skeletal, visceral and dermatoglyphic abnormalities, cardiac anomalies, and immunological defects \[[@B1],[@B2]\]. Kabuki syndrome has an incidence of 1 in 32,000, likely largely underestimated \[[@B3]\]. The vast majority of reported cases are sporadic. After initial and controversial data that associated this condition to chromosomal rearrangement \[[@B4],[@B5]\], mutations in the *MLL2*gene identified the underlying cause of Kabuki syndrome in approximately 72% of affected individuals \[[@B6],[@B7]\]. The encoded MLL2 protein is a member of the Mixed Lineage Leukemia (MLL) family of histone methyl transferases (HMT). The MLL proteins (MLLs) are part of the SET (Su(var)3-9, Enhancer-of-zeste, Trithorax) family of proteins \[[@B8]\]. The highly conserved SET domain of MLLs confers histone methyltransferase activity, which is the core function of HMTs. MLLs are important in the epigenetic control of active chromatin states \[[@B9]\]. They act as transcriptional co-activators and are involved in embryogenesis and development through, for example, regulation of the expression of the *HOX*genes and their interaction with nuclear receptors \[[@B10],[@B11]\].

The *MLL2*gene encodes a multi-domain-containing protein of 5,537 amino acid residues that can methylate the Lys-4 position of histone H3 (H3K4), an epigenetic mark correlated with transcriptional active chromatin \[[@B12],[@B13]\]. MLL2 is involved in estrogen receptor α (ERα)-mediated signal transduction, acting as a coactivator of a complex that includes ASH2, RBQ3, and WDR5 \[[@B14]\].

In the present study, by direct sequencing of DNA samples from 62 Kabuki patients we identified 42 *MLL2*variants, 38 of which are novel.

Methods
=======

Subjects and Clinical Data
--------------------------

Our cohort comprised 62 index patients clinically diagnosed as affected by Kabuki syndrome (Figure [1](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}). Patients were enrolled after obtaining appropriate informed consent by the physicians in charge and approval by the respective local ethics committees. Patients were included in this study whether at least four of the following inclusion criteria were present: 1) long palpebral fissures with eversion of the lateral portion of lower eyelid; 2) broad, arched eyebrows with sparseness; 3) short nasal columella with depressed nasal tip; 4) large, prominent or cupped ears; 5) developmental delay-mental retardation \[[@B15]\].

![**Facial features of Kabuki syndrome patients**. Representative images of Kabuki patients with *MLL2*mutations.](1750-1172-6-38-1){#F1}

###### 

Clinical features of our cohort of Kabuki syndrome patients

  ---------------------------------------------- ---------------------
  **Gender**                                     36/62 (58.1%) Male
                                                 26/62 (41.9) Female
  **General features**                           
  Short stature                                  38/62 (61.2)
  Microcephaly                                   18/62 (29)
  Neonatal problems                              42/62 (67.7)
  **Facial**                                     
  Long palpebral fissures                        59/62 (95.2)
  Everted lower eyelids                          53/62 (85.5)
  Large dysplastic ears                          56/62 (90.3)
  Arched eyebrows, sparse lateral one third      51/62 (82.2)
  Flat nasal tip                                 43/62 (69.3)
  Abnormal dentition                             33/62 (53.2)
  High/cleft palate                              37/62 (59.7)
  Strabismus                                     26/62 (41.9)
  Blue sclerae                                   11/62 (17.7)
  Micrognathia                                   20/62 (32.2)
  Ptosis                                         32/62 (51.6)
  Broad nasal root                               39/62 (62.9)
  Oligodontie                                    23/62 (37.1)
  Thin upper and full lower lip                  44/62 (71)
  **Limb/skeletal**                              
  Persistent fetal pads                          47/62 (75.8)
  Brachy/clinodactyly                            39/62 (62.9)
  Lax joints                                     30/62 (48.4)
  Hip dislocation                                8/62 (12.9)
  **Visceral anomalies**                         
  Cardiac anomalies                              37/62 (59.7)
  Urogenital anomalies                           24/62 (38.7)
  **Neurologic**                                 
  MR                                             52/62 (83.9)
  Hypotonia                                      37/62 (59.7)
  Seizures                                       13/62 (21.4)
  **Other clinical features (most recurrent)**   
  frequent infections                            26/62 (41.9)
  leftearly breast development                   10/62 (16.1)
  lefthypoacusia                                 7/62 (11.3)
  skeletal anomalies                             6/62 (9.7)
  leftthyroid anomalies                          4/62 (6.9)
  leftagenesis/dysgenesis corpus callosum        3/62 (5.2)
  ---------------------------------------------- ---------------------

Samples preparation
-------------------

Genomic DNAs were extracted from fresh and/or frozen peripheral blood leukocytes of the probands and their available family members using an automated DNA extractor and commercial DNA extraction Kits (EZ1, Qiagen, Hilden, Germany).

PCR-based sequencing of MLL2
----------------------------

Primers were designed using the Primer 3 Output program (<http://frodo.wi.mit.edu/primer3/>) to amplify the 54 coding exons of *MLL2*(RefSeq NM_003482.3) gene including the intronic flanking sequences. Amplicons and primers were checked both by BLAST and BLAT against the human genome to ensure specificity. A complete list of primers is reported in Additional file [1](#S1){ref-type="supplementary-material"}, Table S1. The amplified products were subsequently purified and sequenced with a ready reaction kit (BigDye Terminator v1.1 Cycle, Applied Biosystems). The fragments obtained were purified using DyeEx plates (Qiagen) and resolved on an automated sequencer (3130xl Genetyc analyzer DNA Analyzer, ABI Prism). Sequences were analyzed using the Sequencer software (Gene Codes, Ann Arbor, Michigan). Whenever possible the mutations identified were confirmed on a second independent blood sample. The issue of whether the novel *MLL2*missense alterations were causative mutations or neutral polymorphisms was addressed by searching dbSNP (<http://www.ncbi.nlm.nih.gov/SNP>) for their presence; the screening of 100 alleles from healthy unrelated control subjects and from the 1000 Genomes database \[[@B16]\] were used to assess their presence/absence in the general population. All existing and new mutations were described following the recommendations of the Human Genome Variation Society (<http://www.hgvs.org/mutnomen>).

In silico analysis
------------------

The putative causal and functional effect of each identified nucleotide variant was estimated by using the following *in silico*prediction tools: Polyphen <http://genetics.bwh.harvard.edu/pph>, Align GVGD <http://agvgd.iarc.fr/agvgd_input.php>, and MutPred <http://mutdb.org/profile>. Splice sites variants were evaluated for putative alteration of regulatory process at the transcriptional or splicing level with NetGene2 <http://www.cbs.dtu.dk/services/NetGene2> and NNSPLICE <http://www.fruitfly.org/seq_tools/splice.html>. RESCUE-ESE <http://genes.mit.edu/burgelab/rescue-ese/> and Fas-ESS <http://genes.mit.edu/fas-ess/> online tools were used to predict exon-splicing enhancer and silencer, respectively. RepeatMasker <http://www.repeatmasker.org/> was used to screen DNA sequences for the presence of direct repeats. The Coils program <http://www.ch.embnet.org/software/COILS_form.html> was employed to calculate the probability that the variant induces a conformational change in the coiled-coil domains. Finally multiple species alignment of MLL2 protein was made with the ClustalW software <http://www.ebi.ac.uk/Tools/clustalw2/index.html> using the following orthologs sequences obtained through the Ensembl genome browser <http://www.ensembl.org>: *P. troglodytes*(ENSPTRP00000041051), *M. musculus*(ENSMUSP00000023741), *C. familiaris*(gENSCAFP00000012833), *B. taurus*(ENSBTAP00000019193), *X. troplicalis*(ENSXETP00000024427), and *D. rerio*(ENSDARP00000053862).

Results and Discussion
======================

Exome sequencing recently revealed that mutations in the histone methyltransferase *MLL2*gene are a major cause of Kabuki syndrome \[[@B6]\]. In a collaborative effort that involved Italian Institutes, except one, we enrolled 62 individuals with a clinical diagnosis of sporadic Kabuki syndrome (Table [1](#T1){ref-type="table"}). We detected nucleotide variants in 73% of the patients (45/62) by direct sequencing of all 54 exons of the *MLL2*gene; the vast majority of which are novel (90%, 38/42 different variants) (Figure [2](#F2){ref-type="fig"}, Additional file [1](#S1){ref-type="supplementary-material"}, Table S2, Additional file [2](#S2){ref-type="supplementary-material"}, Figure S1 and below) \[[@B6],[@B7]\].

![**Mutation spectrum of *MLL2*in our cohort of Kabuki syndrome patients**. Upper panel: genomic structure of the *MLL2*gene including 54 coding exons (black rectangles), the 3\'untranslated region (red rectangle) and introns (black horizontal line). Mutations are represented in black (nonsense = 16), red (indel = 3), blue (splice sites = 3), and green (frameshift = 13). Middle figure: MLL2 protein domain structures, PHD, plant homeodomain finger; HMG-box, high mobility group; CC, Coiled Coil; LXXLL domain, FYRN, FY-rich domain, N-terminal region; FYRC, FY-rich domain, C-terminal region; SET, (Su(var)3-9, Enhancer-of-zeste, Trithorax) domain; PostSET: PostSET domain. Lower panel: evolutionary comparison of the protein sequences flanking the 7 missense mutations identified in the human MLL2 protein with their orthologous counterparts in seven species. The position of the amino acid change is indicated with a star.](1750-1172-6-38-2){#F2}

Nonsense and frameshift mutations
---------------------------------

In agreement with previous reports we identified a majority of truncating mutations (70%, 29/42), three of which were reported previously (Figure [2](#F2){ref-type="fig"}, Additional file [1](#S1){ref-type="supplementary-material"}, Table S2) \[[@B6],[@B7]\]. Most of the variants are predicted, if translated, to encode shorter MLL2 proteins either by loss of the entire C-terminal region or parts of it (Figure [2](#F2){ref-type="fig"}). This region harbors highly conserved domains that are found in a variety of chromatin-associated proteins \[[@B17]-[@B19]\]: (i) the helical LXXLL regions involved in the recruitment of the MLL2 complex to the promoters of ERα target genes (Figure [2](#F2){ref-type="fig"}); (ii) FYRN and FYRC sequence motifs, two poorly characterized phenylalanine/tyrosine-rich regions of around 50 and 100 amino acids \[[@B20]\], respectively; and (iii) a catalytic SET motif that confers histone methyltransferases activity.

Although it has not been yet experimentally verified for the *MLL2*gene, the prevalence of premature termination mutations may result in the partial transcripts degradation through nonsense-mediated mRNA decay (NMD). NMD is an evolutionarily conserved process that typically degrades transcripts containing premature termination codons (PTCs) to prevent translation of unnecessary or aberrant and possible transcripts \[[@B21]\]. The NMD process takes place when PTCs are located more than 50-55 nucleotides upstream of an exon-exon junction \[[@B22]\]. As 86% (25/29) of such detected *MLL2*mutations follow this rule it is likely that the consequent MLL2 haploinsufficiency could be the driving force for the onset of the Kabuki syndrome.

Indel variants
--------------

Our screen revealed three not yet described indel variants located in the C-terminal region of the protein (see samples KB71, KB77, and KB53 in Additional file [1](#S1){ref-type="supplementary-material"}, Table S2). They might have resulted from slipped mispairing between direct repeats or through the insertion or deletion of a single base within a mononucleotide tract (Additional file [1](#S1){ref-type="supplementary-material"}, Table S3), as already reported \[[@B23]\].

COILS algorithm predicted the amplification of one of the five coiled-coil putative domains for the c.11819_11836dupTTCAACAACAGCAGCAGC (p.Lys3940_Gln3945dup) (Figure [2](#F2){ref-type="fig"} and data not shown), a domain involved in protein-protein interaction. This variant was inherited from the apparently asymptomatic mother. It is thus impossible to conclusively determine the pathogenic nature of the resulting protein.

Splice site variants
--------------------

We detected 3 variants located at the splice site junctions, two of which are novel \[[@B7]\] (Additional file [1](#S1){ref-type="supplementary-material"}, Table S2); the *insilico*modeling predicted complete or partial abrogation of the junction formation with a pathogenic impact. The c.400+1G\>A, occurring within the invariant GT donor splice site in intron 3-4, results in the disruption of the canonical splice site and it is expected to produce an aberrant protein of only 135 residues. The c.401-3A\>G, occurring 3 bp away from the next intron-exon junction, is predicted to create a new acceptor splice site at position -3 within intron 3-4 that could lead to a frameshift encoding a mutant protein with a premature stop at 84 codons downstream. Finally, c.13999+5G\>A decreases the donor site score prediction, possibly resulting in a less efficient intron splicing. Unfortunately, RNA from these patients was unavailable preventing further investigation of the effect of these variants.

Missense variants
-----------------

Missense *de novo*variants have already been found in Kabuki patients. Ng and colleagues reported 8 pathogenic missense variants, two of which were recurrent in affected patients. As these were all mapping within the last exon of *MLL2*that encodes the different conserved C-terminal domains of the protein (see above), the authors suggested that such mutations are tolerated, while mutations elsewhere are lethal. By *in silico*analysis, Paulussen *et al*. proposed the pathogenicity of two missense variants located within that C-terminal region \[[@B6],[@B7]\]. We detected seven patients with a single or two missense variants (KB28 and KB38 patients; Additional file [1](#S1){ref-type="supplementary-material"}, Table S2). PCR amplification, cloning and sequencing showed that both sets of the two sequence changes in KB28 and KB38 patients are located on one allele. From a phenotypic point of view, the two patients with pairs of missense variants do not appear to be more severely affected than affected individuals with single variants. Sequencing of the corresponding exons in the KB38 parents demonstrated that both variants arose *de novo*, while the KB28 patient inherited the variant from the apparently asymptomatic mother. We had also accessed to DNA of parents of carriers of missense variants (Additional file [1](#S1){ref-type="supplementary-material"}, Table S2). Yet, in both cases the *MLL2*variant was inherited from the apparently asymptomatic father.

The missense variants are distributed across the entire length of the *MLL2*gene (Figure [2](#F2){ref-type="fig"}). They were not found in 50 healthy unrelated control samples and were absent from the 1000 Genomes database \[[@B16]\]. The putative functional relevance and pathogenicity of these *MLL2*missense variants were predicted by *in silico*software. The PolyPhen program, which predicts possible impact of an amino acid substitution on the structure and function of a human protein, identified only the p.Pro2841Thr variant as possibly damaging. Accordingly to the criteria of Align-GVGD all missense variants were predicted to be deleterious (Table [2](#T2){ref-type="table"}). Finally, we used the computational model MutPred, designed to classify an amino acid substitution as disease-associated or neutral in human. MutPred predicted that four of the identified missense variants have a high probability (≥0,5) of being deleterious and generated *in silico*hypothesis for the possible pathological mechanism for three of them (Table [2](#T2){ref-type="table"}). The analysis of the mutated residues in 7 MLL2 proteins orthologs showed that.all the missense variants occurred at amino acid residues evolutionarily conserved (Figure [2](#F2){ref-type="fig"}).

###### 

In *silico*prediction of pathogenic effect of *MLL2*missense and splice site variants

                                                                                                Prediction of damaging effect at the protein level                                                                                                                                                                           
  -------- -------------- --------------------------- ----------------------------------------- ---------------------------------------------------- -------------------------- --------------- ------------------------------------------------------------------------------------------------------- -------------------- --------------------
  KB32     11             c.3773G\>A                  p.Arg1258Gln                              benign                                               deleterious                0.16            loss of loop (p = 0.0288, loss of catalytic residue at R1258 (p = 0.0301); gain of helix (p = 0.0349)   no change            no change
  KB28     15             c.\[4249A\>G;4252C\>A\]     p.\[Met1471Val;Leu1418Met\]               benign; benign                                       deleterious; deleterious   0.46; 0.47      none; none                                                                                              no change            gain of one ESS
  KB34     16             c.4565A\>G                  p.Gln1522Arg                              benign                                               deleterious                0.50            none                                                                                                    loss of one ESE      no change
  KB27     34             c.8521C\>A                  p.Pro2841Thr                              possibly damaging                                    deleterious                0,24            gain of phoshorylation P2841 (p = 0.028)                                                                gain of two ESEs     loss of one ESS
  KB38     48             c.\[15084C\>G;15100T\>G\]   p.\[Asp 5028Glu;Phe5034Val\]              benign; benign                                       deleterious; deleterious   0.42; 0.56      none; none                                                                                              gain of three ESEs   loss of three ESSs
  KB76     48             c.1517A\>C                  p.His5059pro                              benign                                               deleterious                0,71            none                                                                                                    no change            no change
  KB17     50             c.16019G\>A                 p.Arg5340Gln                              benign                                               deleterious                0,53            gain of ubiquitination at K5344 (p = 0.0396)                                                            gain of two ESEs     no change
                                                                                                                                                                                                                                                                                                                             
  **ID**   **Intron**     **Mutation**                **Splice site modification prediction**   **Predicted Protein**                                **Conclusion**                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                             
                                                                                                **NetGene**                                          **NNSplice**                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                             
  KB31     Intron 3-4     c.400+1G\>A                 Loss of DS                                Loss of DS                                           135 AA with novel 2 AA     deleterious                                                                                                                                  
  KB20     Intron 3-4     c.401-3A\>G                 New AS at-3                               New AS at-3                                          217 AA with novel 84 AA    deleterious                                                                                                                                  
  KB29     Intron 42-43   c\. 13999+5 G\>A            Lower confidence of DS prediction         Lower confidence of DS prediction                                               unpredictable                                                                                                                                

Finally, we employed RESCUE-ESE and Fas-ESS tools on missense variants and frameshift mutations to predict associated splicing phenotypes by identifying sequence changes that disrupt or alter predicted Exonic Splicing Enhancers (ESE) and Exonic Splicing Silencers (ESS). ESE and ESS are short oligonucleotides that can enhance or inhibit pre-mRNA splicing when present in exons, playing important roles in constitutive and alternative splicing. A variation that disrupts an ESE, for instance, could cause exon skipping which would result in the exclusion of an entire exon from the mRNA transcript. Conversely, a substitution in the ESS sequence promotes the use of adjacent splice sites, often contributing to alternative splicing. As reported in Table [2](#T2){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}, Table S3, we found that some of the *MLL2*mutations lead to creation of new ESEs and/or to disruption of predicted wild type ESEs/ESSs. As secondary structures or adjacent negative elements also participate to the modulation of the splicing event mediated by ESE and ESS, we retain that association to functional studies will enable to better understand the role of the reported cases of ESEs/ESSs disruption or alteration in the complex phenotypic spectrum observed in the Kabuki patients.

Conclusions
===========

Our study increases the number of identified *MLL2*mutations and variants, and emphasizes some characteristics of the spectrum of *MLL2*mutations associated with this pathology, further providing insight into its etiology. The *in silico*analysis predicts that the identified *MLL2*missense, splice-site and indel variants might be pathogenic. Other studies reported the presence of such *MLL2*variants predicted to be associated with the disease. However, their biological significance and pathogenicity were not unambiguously demonstrated; therefore further and more functionally oriented studies are needed to understand the nature of these variants and their possible role in the disease. Solving these issues is relevant to avoid any incorrect interpretation and diagnosis of other Kabuki cases carrying such *MLL2*variants.

We were unable to found any detectable point mutation and/or small del/dup in the coding region of *MLL2*gene in 27% (17/62) of the Kabuki syndrome patients. Mutations in *MLL2*regulatory regions, exon microduplications and/or microdeletions, as well as genetic heterogeneity of the syndrome may account for these negative results. Alternatively, some of these patients might have been misdiagnosed as a result of the complex clinical spectrum covered by this pathology, thus possibly highlighting the need to more accurately select Kabuki cases before conducting the analysis.

In summary, this study underlines the relevance of mutational screening of the *MLL2*gene among patients with Kabuki syndrome. The identification of a large spectrum of *MLL2*mutations will offer the opportunity to improve the actual knowledge on the clinical basis of this multiple congenital mental retardation syndrome, to design functional studies to understand the molecular mechanisms underlying the disease, to establish genotype-phenotype correlations, to improve the clinical management, and to identify potential targets for therapy.
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